BRAF V600E- and CTNNB1 T41A-bearing colon cancer was resistant to 5-FU, oxaliplatin and cetuximab. (A) Growth of PDCCX tumors carrying BRAF V600E and CTNNB1 T41A mutations following the treatment of tumor-bearing mice (n=5) with saline, 5-FU, oxaliplatin or cetuximab. (B) Inhibition of tumor growth by 5-FU, oxaliplatin and cetuximab, relative to that in tumors treated with saline alone. CTNNB1, β-catenin; 5-FU, 5-fluorouracil.